Intervet/Schering-Plough Animal Health, a subsidiary of Merck & Co. Inc. of Whitehouse Station, N.J., reported yesterday that it is reintroducing the Vista vaccine line to the U.S. market.
The vaccines are indicated to protect beef and dairy cattle against Infectious Bovine Rhinotracheitis, Bovine Viral Diarrhea (BVD Type 1 and Type 2), Parainfluenza3, Bovine Respiratory Syncytial Virus (BRSV), leptospirosis, vibriosis, Mannheimia haemolytica and Pasteurella multocida.
The Vista line of vaccines was introduced in 2005 but a stop sale was issued in 2009 due to a variability issue with the BRSV antigen. Intervet/Schering-Plough Animal Health said it has been working with the U.S. Department of Agriculture to resolve the issue.
“Intervet/Schering-Plough Animal Health is committed to providing innovative, high-quality animal health products that [beef and dairy cattle] veterinarians and producers trust,” said Ron Bryant, who leads the U.S. non-confined beef and dairy cattle business for Intervet/Schering-Plough Animal Health. “We are excited to welcome back Vista to our portfolio of products, are committed to being a reliable supplier and are confident Vista will deliver the protection needed to keep dairy animals healthy and productive.”
Vista vaccines are available through veterinarians and animal health suppliers.